PDS Biotechnology (NASDAQ:PDSB) Given New $7.00 Price Target at B. Riley

PDS Biotechnology (NASDAQ:PDSB) had its target price trimmed by B. Riley from $9.00 to $7.00 in a report issued on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock. B. Riley also issued estimates for PDS Biotechnology’s Q4 2024 earnings at ($0.29) EPS, FY2024 earnings at ($1.12) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($1.52) EPS and FY2028 earnings at ($1.77) EPS.

Several other analysts have also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of PDS Biotechnology in a research note on Friday, November 15th. StockNews.com lowered PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. Finally, Alliance Global Partners upgraded PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $11.67.

PDS Biotechnology Stock Up 1.9 %

Shares of NASDAQ:PDSB opened at $2.15 on Monday. The company’s fifty day moving average is $3.06 and its 200-day moving average is $3.17. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. PDS Biotechnology has a 52 week low of $1.53 and a 52 week high of $6.68. The company has a market capitalization of $80.43 million, a PE ratio of -1.85 and a beta of 1.93.

Institutional Trading of PDS Biotechnology

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in PDS Biotechnology by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after buying an additional 82,135 shares in the last quarter. Geode Capital Management LLC raised its position in shares of PDS Biotechnology by 9.8% during the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after acquiring an additional 37,142 shares during the last quarter. Inspirion Wealth Advisors LLC lifted its stake in shares of PDS Biotechnology by 1.4% during the second quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock valued at $1,054,000 after acquiring an additional 4,917 shares during the period. Blair William & Co. IL boosted its holdings in PDS Biotechnology by 204.4% in the second quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after acquiring an additional 81,743 shares during the last quarter. Finally, XTX Topco Ltd increased its position in PDS Biotechnology by 241.8% in the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock worth $257,000 after purchasing an additional 47,528 shares during the period. 26.84% of the stock is owned by institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.